Sense Diagnostics (Cincinnati, OH) was founded by Drs. Ope Adeoye, associate professor of Emergency Medicine and Neurosurgery, George Shaw, Associate Professor of Emergency Medicine, Matthew Flaherty, Professor of Neurology and Joseph Clark, Professor, the Department of Neurology. The company is developing a new medical device, “SENSE”, that is capable of quickly, and continuously, monitoring brain activity, in particular changes to the brain resulting from hemorrhage/bleeding, swelling or seizures. SENSE works by sending very low power electro-magnetic pulses across the affected person’s brain that are detected and analyzed by computer. SENSE offers the capability of earliest possible detection of brain derangement, allowing for immediate intervention, and more favorable outcomes. Because of its portability, SENSE will be amenable for use in myriad environments (e.g., ambulances, emergency room, operating room, or anywhere where patients are susceptible to neurologic worsening).
In 2013, the Sense team, led by Dr. Adeoye, were awarded $40,000 from the UCTAC to advance SENSE from an early stage development to a bona fide
commercial opportunity. UCTAC introduced the team to Mr. Dan Kincaid, a local entrepreneur and now CEO of Sense Diagnostics. After its founding, Sense Diagnostics would go on to receive Phase I ($150,000) and Phase II ($750,000) SBIR funding to further advance the Sense technology.
More recently, Sense Diagnostics closed series A funding in Q1, 2017, bringing the company’s total funding level to about $2.3MM to date.